2023 Q1 Form 10-K Financial Statement

#000141057823000234 Filed on March 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $9.449M $9.390M $34.69M
YoY Change 8.72% -12.91% -19.64%
Cost Of Revenue $3.994M $3.633M $13.96M
YoY Change 75.36% 16.35% 26.33%
Gross Profit $5.455M $5.757M $20.73M
YoY Change -14.94% -24.84% -35.45%
Gross Profit Margin 57.73% 61.31% 59.77%
Selling, General & Admin $8.463M $8.506M $34.29M
YoY Change -7.61% -23.25% -4.09%
% of Gross Profit 155.14% 147.76% 165.38%
Research & Development $4.214M $3.402M $15.12M
YoY Change -0.68% -44.57% -7.7%
% of Gross Profit 77.25% 59.09% 72.92%
Depreciation & Amortization $258.6K $223.2K $688.6K
YoY Change 18.87% 4.11% 26.88%
% of Gross Profit 4.74% 3.88% 3.32%
Operating Expenses $13.35M $11.91M $52.25M
YoY Change -6.04% -30.85% -4.75%
Operating Profit -$7.892M -$6.356M -$31.52M
YoY Change 1.29% -33.52% 38.59%
Interest Expense -$63.17K $4.572M $132.6K
YoY Change -886.97% -1050.08% 373.44%
% of Operating Profit
Other Income/Expense, Net $565.7K -$74.13K -$2.383M
YoY Change -148.14% -6.53%
Pretax Income -$7.326M -$1.859M -$33.91M
YoY Change -18.3% -81.49% 34.04%
Income Tax -$1.093M -$1.093M
% Of Pretax Income
Net Earnings -$7.326M -$766.1K -$32.81M
YoY Change -18.3% -91.77% 33.61%
Net Earnings / Revenue -77.53% -8.16% -94.59%
Basic Earnings Per Share -$0.17 -$0.02 -$0.75
Diluted Earnings Per Share -$0.17 -$0.02 -$0.75
COMMON SHARES
Basic Shares Outstanding 43.66M 43.64M 43.57M
Diluted Shares Outstanding 43.68M 43.57M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.05M $22.14M $22.14M
YoY Change -55.72% -57.53% -57.53%
Cash & Equivalents $19.05M $22.14M $22.14M
Short-Term Investments
Other Short-Term Assets $1.863M $2.489M $2.489M
YoY Change -33.67% -13.34% -13.34%
Inventory $1.726M $3.462M $3.462M
Prepaid Expenses
Receivables $5.528M $5.665M $5.665M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $28.16M $33.76M $33.76M
YoY Change -49.57% -47.5% -47.5%
LONG-TERM ASSETS
Property, Plant & Equipment $10.70M $10.74M $23.35M
YoY Change 36.26% 108.57% 25.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.445M $4.437M $1.734M
YoY Change -5.11% -10.51% -10.79%
Total Long-Term Assets $29.30M $29.47M $29.47M
YoY Change 6.86% 16.86% 16.86%
TOTAL ASSETS
Total Short-Term Assets $28.16M $33.76M $33.76M
Total Long-Term Assets $29.30M $29.47M $29.47M
Total Assets $57.46M $63.23M $63.23M
YoY Change -30.99% -29.37% -29.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.995M $1.655M $1.655M
YoY Change -37.94% -41.0% -41.0%
Accrued Expenses $5.824M $850.6K $4.682M
YoY Change -21.41% -18.53% -27.67%
Deferred Revenue $1.517M
YoY Change -22.11%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.44M $9.715M $9.715M
YoY Change -28.87% -29.04% -29.04%
LONG-TERM LIABILITIES
Long-Term Debt $5.011M $5.000M $5.000M
YoY Change
Other Long-Term Liabilities $13.06M $13.14M $13.14M
YoY Change -0.85% -0.82% -0.82%
Total Long-Term Liabilities $18.07M $5.000M $18.14M
YoY Change 37.19% -62.27% 36.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.44M $9.715M $9.715M
Total Long-Term Liabilities $18.07M $5.000M $18.14M
Total Liabilities $28.51M $27.86M $27.86M
YoY Change 2.38% 3.4% 3.4%
SHAREHOLDERS EQUITY
Retained Earnings -$261.3M -$254.0M
YoY Change 13.54% 14.83%
Common Stock $43.85K $43.64K
YoY Change 0.8% 0.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.96M $35.37M $35.37M
YoY Change
Total Liabilities & Shareholders Equity $57.46M $63.23M $63.23M
YoY Change -30.99% -29.37% -29.37%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$7.326M -$766.1K -$32.81M
YoY Change -18.3% -91.77% 33.61%
Depreciation, Depletion And Amortization $258.6K $223.2K $688.6K
YoY Change 18.87% 4.11% 26.88%
Cash From Operating Activities -$3.108M -$5.340M -$28.23M
YoY Change -61.72% -2.75% 101.59%
INVESTING ACTIVITIES
Capital Expenditures $509.7K $206.1K $6.087M
YoY Change -28.24% -112.32% 67.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$682.9K -$206.1K -$6.456M
YoY Change -19.47% -87.68% 50.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities 684.3K 5.000M 4.960M
YoY Change -1795.49% -6278.94% 593.46%
NET CHANGE
Cash From Operating Activities -3.108M -5.340M -28.23M
Cash From Investing Activities -682.9K -206.1K -6.456M
Cash From Financing Activities 684.3K 5.000M 4.960M
Net Change In Cash -3.096M -546.4K -29.99M
YoY Change -66.03% -92.46% 70.45%
FREE CASH FLOW
Cash From Operating Activities -$3.108M -$5.340M -$28.23M
Capital Expenditures $509.7K $206.1K $6.087M
Free Cash Flow -$3.618M -$5.546M -$34.32M
YoY Change -59.02% 45.24% 94.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43573215
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43359186
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38818990
CY2020 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2020 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2020 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2021 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2021 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2021 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2022 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2022 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2022 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001175151
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43635715
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43478487
CY2014Q2 ctso Defined Contribution Eligibility Term
DefinedContributionEligibilityTerm
P3M
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36792
CY2022 dei Entity Registrant Name
EntityRegistrantName
CYTOSORBENTS CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0373793
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
305 College Road East
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
CY2022 dei City Area Code
CityAreaCode
732
CY2022 dei Local Phone Number
LocalPhoneNumber
329-8885
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
CTSO
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
61461000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43663009
CY2022 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2022 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2022 dei Auditor Firm
AuditorFirmId
100
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22144567
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52137707
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
76041
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
60539
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5664941
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4523430
CY2022Q4 us-gaap Inventory Net
InventoryNet
3461586
CY2021Q4 us-gaap Inventory Net
InventoryNet
4766098
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2488597
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2871655
CY2022Q4 us-gaap Assets Current
AssetsCurrent
33759691
CY2021Q4 us-gaap Assets Current
AssetsCurrent
64298890
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10743032
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5150886
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1687459
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1687459
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12603901
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13423472
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4437447
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4958575
CY2022Q4 us-gaap Assets
Assets
63231530
CY2021Q4 us-gaap Assets
Assets
89519282
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1655173
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2805235
CY2022Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7950440
CY2021Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10314341
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108939
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
570566
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9714552
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13690142
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13142005
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13250943
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5000000
CY2022Q4 us-gaap Liabilities
Liabilities
27856557
CY2021Q4 us-gaap Liabilities
Liabilities
26941085
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43635715
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43478487
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
43635
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
43478
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
287000021
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
283194429
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2329195
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
525585
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253997878
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221185295
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35374973
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62578197
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63231530
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89519282
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
34688809
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
43165527
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
41004601
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13955752
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11047350
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11052409
CY2022 us-gaap Gross Profit
GrossProfit
20733057
CY2021 us-gaap Gross Profit
GrossProfit
32118177
CY2020 us-gaap Gross Profit
GrossProfit
29952192
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15118907
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16380930
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8810561
CY2022 us-gaap Professional Fees
ProfessionalFees
2847899
CY2021 us-gaap Professional Fees
ProfessionalFees
2731515
CY2020 us-gaap Professional Fees
ProfessionalFees
3048242
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34288130
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35750477
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28463723
CY2022 us-gaap Operating Expenses
OperatingExpenses
52254936
CY2021 us-gaap Operating Expenses
OperatingExpenses
54862922
CY2020 us-gaap Operating Expenses
OperatingExpenses
40322526
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-31521879
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-22744745
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10370334
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
132597
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
28007
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1201067
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2448583
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2577913
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2607139
CY2022 ctso Miscellaneous Income
MiscellaneousIncome
-67303
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2383289
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2549906
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1406072
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33905168
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25294651
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8964262
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1092585
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-736003
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1127074
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32812583
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24558648
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7837188
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43573215
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43359186
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38818990
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-32812583
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24558648
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-7837188
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1803610
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2259663
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2260056
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31008973
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22298985
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10097244
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3418042
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3513671
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
80214008
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
657780
CY2020 ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
1509322
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2260056
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-7837188
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
79215579
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4020819
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-90000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
928417
CY2021 ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
805199
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2832
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2259663
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24558648
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62578197
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3423517
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
40358
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
380091
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1803610
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
42499
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-32812583
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35374973
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-32812583
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24558648
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-7837188
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
376574
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2183317
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1193949
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
882621
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
731578
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
660788
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
249008
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
398035
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-8354
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-512
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-102310
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-132303
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
635606
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2448583
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2577913
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2607139
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3423517
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4020819
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3513671
CY2020 ctso Amortization Of Loan Acquisition Costs
AmortizationOfLoanAcquisitionCosts
322812
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1288422
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-420578
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
326860
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-945352
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2350547
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
461512
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
22187
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-280915
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1076849
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-52678
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
135857
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3248978
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2426810
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1107352
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28234282
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14005599
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5613286
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6087365
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3641248
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
708395
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
368211
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
640013
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
967823
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6455576
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4281261
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1676218
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5000000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1410900
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
16410900
CY2020 ctso Payment Of Non Refundable Final Fee Upon Termination Or Maturity Of Debt Instrument
PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument
375000
CY2022 ctso Payments For Equity Contributions Net Of Fees Incurred
PaymentsForEquityContributionsNetOfFeesIncurred
40358
CY2021 ctso Payments For Equity Contributions Net Of Fees Incurred
PaymentsForEquityContributionsNetOfFeesIncurred
90000
CY2020 ctso Payments For Equity Contributions Net Of Fees Incurred
PaymentsForEquityContributionsNetOfFeesIncurred
-80214008
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
805199
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1509322
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4959642
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
715199
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66348330
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-262924
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-24774
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
130357
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29993140
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17596435
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
59189183
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53825166
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71421601
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12232418
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23832026
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53825166
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71421601
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1127647
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
42499
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
359965
CY2022 us-gaap Stock Issued1
StockIssued1
380091
CY2021 us-gaap Stock Issued1
StockIssued1
928417
CY2020 us-gaap Stock Issued1
StockIssued1
657780
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1687459
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1687459
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23832026
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53825166
CY2022 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. BASIS OF PRESENTATION:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents Medical Inc., its wholly owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly owned European subsidiary (the “European Subsidiary”). In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited, and CytoSorbents France SAS, the wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. These entities are collectively referred to as the “Company”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In years prior to December 31, 2020, the Company’s consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company’s cash, cash equivalents and restricted cash balances were approximately $23.8 million, which the Company expects will fund the Company’s operations beyond twelve months from the issuance of these consolidated financial statements. As a result, the Company has determined that the going concern risk has been substantially mitigated.</p>
CY2022Q4 us-gaap Cash
Cash
23800000
CY2022 ctso Number Of Countries Where Flagship Product Is Marketed And Distributed
NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed
75
CY2022Q4 ctso Number Of Patents United States
NumberOfPatentsUnitedStates
18
CY2022 ctso Foreign Currency Transaction Gain Loss Excluding Tax
ForeignCurrencyTransactionGainLossExcludingTax
-2448000
CY2021 ctso Foreign Currency Transaction Gain Loss Excluding Tax
ForeignCurrencyTransactionGainLossExcludingTax
-2578000
CY2020 ctso Foreign Currency Transaction Gain Loss Excluding Tax
ForeignCurrencyTransactionGainLossExcludingTax
2607000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22144567
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52137707
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1687459
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1567871
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3084606
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1280368
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1322736
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
613347
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
358756
CY2022Q3 us-gaap Inventory Adjustments
InventoryAdjustments
599000
CY2022 ctso Wrote Off Patents Costs
WroteOffPatentsCosts
636000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
582000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
615000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
285000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for doubtful accounts and recoverability of patents are significant estimates in these consolidated financial statements.</p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company’s revenues are from product sales in Germany. Substantially all of the Company’s grant and other income are from grant agencies in the United States. (See Note 3 for further information relating to the Company’s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, two distributors accounted for approximately 27% of outstanding grants and accounts receivables. As of December 31, 2021, one distributor accounted for approximately 12% of outstanding grants and accounts receivables. For the years ended December 31, 2022, 2021 and 2020, no agency, distributor/strategic partners or direct customer represented more than 10% of the Company’s total revenue.</p>
CY2022 ctso Threshold Used For Calculating Concentration Of Risk
ThresholdUsedForCalculatingConcentrationOfRisk
0.27
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
34688809
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
43165527
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
41004601
CY2022 ctso Number Of Primary Revenue Streams
NumberOfPrimaryRevenueStreams
2
CY2022 ctso Term Of Customer Contracts
TermOfCustomerContracts
P3Y
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3822452
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3000708
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
1694906
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
2251177
CY2022Q4 ctso Contract With Customer Liability Value Of Free Of Charge Goods And Credit Rebates Current
ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent
178134
CY2021Q4 ctso Contract With Customer Liability Value Of Free Of Charge Goods And Credit Rebates Current
ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent
303824
CY2022Q4 ctso Contract With Customer Liability Net Of Free Of Charge Goods And Credit Rebates Current
ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent
1516772
CY2021Q4 ctso Contract With Customer Liability Net Of Free Of Charge Goods And Credit Rebates Current
ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent
1947343
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12639724
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9911505
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1896692
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4760619
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10743032
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5150886
CY2022 us-gaap Depreciation
Depreciation
688565
CY2021 us-gaap Depreciation
Depreciation
571156
CY2020 us-gaap Depreciation
Depreciation
553946
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1947353
CY2022Q4 ctso Clinical Study Costs Payable Current
ClinicalStudyCostsPayableCurrent
1115123
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
848999
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
657320
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4390533
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4701984
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
46914
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
256591
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4437447
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4958575
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
194056
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
160422
CY2020 us-gaap Adjustment For Amortization
AdjustmentForAmortization
106842
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
201000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
201000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
201000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
200000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
196000
CY2022Q4 ctso Accrued Salaries And Commissions Current
AccruedSalariesAndCommissionsCurrent
2862930
CY2021Q4 ctso Accrued Salaries And Commissions Current
AccruedSalariesAndCommissionsCurrent
3270715
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1516772
CY2021Q4 ctso Clinical Study Costs Payable Current
ClinicalStudyCostsPayableCurrent
1767826
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
850630
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1044088
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
622353
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
314068
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
592398
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
769262
CY2022Q4 ctso Customer Rebates
CustomerRebates
166065
CY2021Q4 ctso Customer Rebates
CustomerRebates
214119
CY2022Q4 ctso Accrued Travel And Entertainment Expense Current
AccruedTravelAndEntertainmentExpenseCurrent
99316
CY2021Q4 ctso Accrued Travel And Entertainment Expense Current
AccruedTravelAndEntertainmentExpenseCurrent
88850
CY2022Q4 ctso Accrued Director Fees Current
AccruedDirectorFeesCurrent
97426
CY2021Q4 ctso Accrued Director Fees Current
AccruedDirectorFeesCurrent
71381
CY2022Q4 ctso Sales Payroll And Income Taxes Payable Current
SalesPayrollAndIncomeTaxesPayableCurrent
21871
CY2021Q4 ctso Sales Payroll And Income Taxes Payable Current
SalesPayrollAndIncomeTaxesPayableCurrent
785818
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5556
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2022Q4 ctso Congresses Payable Current
CongressesPayableCurrent
0
CY2021Q4 ctso Congresses Payable Current
CongressesPayableCurrent
40861
CY2022Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7950440
CY2021Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10314341
CY2022 ctso Debt Instrument Non Refundable Fee Upon Termination Or Maturity Percent
DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent
0.025
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5000000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2500000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2500000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5000000
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.098
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5682628
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-12749965
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-6464854
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-3281634
CY2022 ctso Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interests
IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests
-33905168
CY2021 ctso Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interests
IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests
-25294651
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12603901
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13423472
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
13250944
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
13821509
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108939
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
570566
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13142005
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13250943
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1266346
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1656678
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1695677
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1735747
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1776920
CY2022Q4 ctso Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
17232300
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
25363668
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12112724
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
13250944
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2935000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1968000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
937000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y3M18D
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21155203
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18829797
CY2020 ctso Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interests
IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests
-8964262
CY2022 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-1092585
CY2021 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-736003
CY2020 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-1127074
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1092585
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-736003
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1127074
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
47800000
CY2022 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
80% limitation on taxable income
CY2022 ctso Proceeds From Sale Of Net Operating Loss Carryforwards
ProceedsFromSaleOfNetOperatingLossCarryforwards
1093000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31570846
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27190654
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22301154
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
500975
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
1203272
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
305982
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3982147
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2687591
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2194211
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
24121
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
232665
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
135330
CY2022Q4 ctso Deferred Tax Assets Tax Credit Carryforwards Lease Liability
DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability
3724840
CY2021Q4 ctso Deferred Tax Assets Tax Credit Carryforwards Lease Liability
DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability
3997114
CY2020Q4 ctso Deferred Tax Assets Tax Credit Carryforwards Lease Liability
DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability
289287
CY2022Q4 us-gaap Deferred Tax Assets Other Tax Carryforwards
DeferredTaxAssetsOtherTaxCarryforwards
3331625
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43134554
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35311296
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25225964
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39303451
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31242130
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24794474
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3831103
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4069166
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
431490
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
288145
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
183941
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
431490
CY2022Q4 ctso Deferred Tax Liabilities Rights Of Use Assets
DeferredTaxLiabilitiesRightsOfUseAssets
3542958
CY2021Q4 ctso Deferred Tax Liabilities Rights Of Use Assets
DeferredTaxLiabilitiesRightsOfUseAssets
3885225
CY2021Q3 ctso Aggregate Registered Amount For Offerings
AggregateRegisteredAmountForOfferings
150000000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
90000
CY2022Q4 ctso Number Of Long Term Incentive Plans
NumberOfLongTermIncentivePlans
2
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3424000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4021000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3514000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8061321
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6447656
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1936732
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.00210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.00210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.00210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.00028
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.00020
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.00095
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.00034
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.00023
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.00033
CY2022 ctso Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
-0.00015
CY2021 ctso Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
-0.00065
CY2020 ctso Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
-0.00020
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.00006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.00118
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.00170
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.00228
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.00255
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.00216
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.00021
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.00017
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.00044
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00032
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00032
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00028
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00126
CY2021Q4 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
598000
CY2019Q1 ctso Executive Employment Agreements Initial Term
ExecutiveEmploymentAgreementsInitialTerm
P3Y
CY2022Q1 ctso Employment Agreements Automatic Renewal Period
EmploymentAgreementsAutomaticRenewalPeriod
P1Y
CY2022Q1 ctso Employment Agreements Automatic Renewed Period
EmploymentAgreementsAutomaticRenewedPeriod
P1Y
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4218189
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.16
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1579106
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.37
CY2020 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34644
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.50
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
226440
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.60
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
371007
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.46
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5165204
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.36
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M3D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2051980
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.78
CY2021 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y3M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
138037
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.73
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
21756
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.46
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
171413
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.73
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6885978
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.09
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2721205
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.99
CY2022 ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y7M6D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1270155
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.65
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
227204
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.71
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8109824
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.11
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M28D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.55
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4623085
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.32
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1250
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5406000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-9561821
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4167821
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4677530
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6406285
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9307012
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2994846
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.68
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2721205
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
1270155
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
8.65
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
959157
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.65
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3486739
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.10
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4745000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P43M
CY2022Q2 ctso Share Based Compensation Option Milestones Met By The Company Percentage
ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage
0.19
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1114325
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3883000
CY2021Q2 ctso Share Based Compensation Option Milestones Met By The Company Percentage
ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage
0.88
CY2021 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1070000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
8033988
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
19504184
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
11359928
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
4480275
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8707310
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9794903
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10546612
CY2014Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.20
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
442000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
355000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
59200
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8691424
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8495558
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8111353
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9390474
CY2022Q1 us-gaap Gross Profit
GrossProfit
6413788
CY2022Q2 us-gaap Gross Profit
GrossProfit
4944856
CY2022Q3 us-gaap Gross Profit
GrossProfit
3617377
CY2022Q4 us-gaap Gross Profit
GrossProfit
5757036
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7791135
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8357050
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9017338
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6356356
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8966398
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10879222
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12200837
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-766128
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10598847
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12024069
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9760416
CY2021Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10782195
CY2021Q1 us-gaap Gross Profit
GrossProfit
7847403
CY2021Q2 us-gaap Gross Profit
GrossProfit
9313852
CY2021Q3 us-gaap Gross Profit
GrossProfit
7297470
CY2021Q4 us-gaap Gross Profit
GrossProfit
7659452
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2852191
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4924733
CY2020Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11955776
CY2020Q1 us-gaap Gross Profit
GrossProfit
6322468
CY2020Q2 us-gaap Gross Profit
GrossProfit
6545136
CY2020Q3 us-gaap Gross Profit
GrossProfit
7656230
CY2020Q4 us-gaap Gross Profit
GrossProfit
9428358
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2478754
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3297667
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1959652
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2634264
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3452779
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2866956
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-839729
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-677724
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00

Files In Submission

Name View Source Status
ctso-20221231_cal.xml Edgar Link unprocessable
0001410578-23-000234-index-headers.html Edgar Link pending
0001410578-23-000234-index.html Edgar Link pending
0001410578-23-000234.txt Edgar Link pending
0001410578-23-000234-xbrl.zip Edgar Link pending
ctso-20221231.xsd Edgar Link pending
ctso-20221231x10k.htm Edgar Link pending
ctso-20221231xex10d11.htm Edgar Link pending
ctso-20221231xex10d11g001.jpg Edgar Link pending
ctso-20221231xex10d11g002.jpg Edgar Link pending
ctso-20221231xex10d11g003.jpg Edgar Link pending
ctso-20221231xex10d11g004.jpg Edgar Link pending
ctso-20221231xex10d11g005.jpg Edgar Link pending
ctso-20221231x10k_htm.xml Edgar Link completed
ctso-20221231_pre.xml Edgar Link unprocessable
ctso-20221231xex10d11g006.jpg Edgar Link pending
ctso-20221231xex10d30.htm Edgar Link pending
ctso-20221231xex10d30g001.jpg Edgar Link pending
ctso-20221231xex10d30g002.jpg Edgar Link pending
ctso-20221231xex10d30g003.jpg Edgar Link pending
ctso-20221231xex10d30g004.jpg Edgar Link pending
ctso-20221231xex10d30g005.jpg Edgar Link pending
ctso-20221231xex10d30g006.jpg Edgar Link pending
ctso-20221231xex10d30g007.jpg Edgar Link pending
ctso-20221231xex21d1.htm Edgar Link pending
ctso-20221231xex23d1.htm Edgar Link pending
ctso-20221231xex31d1.htm Edgar Link pending
ctso-20221231xex31d2.htm Edgar Link pending
ctso-20221231xex32d1.htm Edgar Link pending
ctso-20221231xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
ctso-20221231_def.xml Edgar Link unprocessable
ctso-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending